Ad-CEA vaccine + avelumab

Ad-CEA vaccine + avelumab is an investigational combination immunotherapy regimen for cancer, specifically metastatic colorectal cancer. The Ad-CEA vaccine is a recombinant adenoviral vector-based therapeutic cancer vaccine encoding carcinoembryonic antigen (CEA), designed to stimulate the immune system to recognize and attack CEA-expressing tumor cells. Avelumab is a fully human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and thereby enhancing T-cell-mediated antitumor responses. This combination aims to synergistically boost antitumor immunity by both priming CEA-specific T cells (via the vaccine) and relieving immune suppression in the tumor microenvironment (via checkpoint inhibition). Clinical trials have evaluated this combination in patients with previously untreated metastatic colorectal cancer, often alongside standard chemotherapy regimens[1][3][4].